These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Preferential Incorporation of Administered Eicosapentaenoic Acid Into Thin-Cap Atherosclerotic Plaques. Sato T; Horikawa M; Takei S; Yamazaki F; Ito TK; Kondo T; Sakurai T; Kahyo T; Ikegami K; Sato S; Sato R; Jinno Y; Kawano H; Naoe S; Arita M; Kashiwagi Y; Setou M Arterioscler Thromb Vasc Biol; 2019 Sep; 39(9):1802-1816. PubMed ID: 31366219 [TBL] [Abstract][Full Text] [Related]
4. Cholesterol crystals and atherosclerotic plaque instability: Therapeutic potential of Eicosapentaenoic acid. John Chapman M; Preston Mason R Pharmacol Ther; 2022 Dec; 240():108237. PubMed ID: 35772589 [TBL] [Abstract][Full Text] [Related]
5. Palmitoylethanolamide Promotes a Proresolving Macrophage Phenotype and Attenuates Atherosclerotic Plaque Formation. Rinne P; Guillamat-Prats R; Rami M; Bindila L; Ring L; Lyytikäinen LP; Raitoharju E; Oksala N; Lehtimäki T; Weber C; van der Vorst EPC; Steffens S Arterioscler Thromb Vasc Biol; 2018 Nov; 38(11):2562-2575. PubMed ID: 30354245 [TBL] [Abstract][Full Text] [Related]
6. Combination of n-3 polyunsaturated fatty acids reduces atherogenesis in apolipoprotein E-deficient mice by inhibiting macrophage activation. Takashima A; Fukuda D; Tanaka K; Higashikuni Y; Hirata Y; Nishimoto S; Yagi S; Yamada H; Soeki T; Wakatsuki T; Taketani Y; Shimabukuro M; Sata M Atherosclerosis; 2016 Nov; 254():142-150. PubMed ID: 27744130 [TBL] [Abstract][Full Text] [Related]
7. Prednisolone-containing liposomes accumulate in human atherosclerotic macrophages upon intravenous administration. van der Valk FM; van Wijk DF; Lobatto ME; Verberne HJ; Storm G; Willems MC; Legemate DA; Nederveen AJ; Calcagno C; Mani V; Ramachandran S; Paridaans MP; Otten MJ; Dallinga-Thie GM; Fayad ZA; Nieuwdorp M; Schulte DM; Metselaar JM; Mulder WJ; Stroes ES Nanomedicine; 2015 Jul; 11(5):1039-46. PubMed ID: 25791806 [TBL] [Abstract][Full Text] [Related]
8. Liposomal Nanotherapy for Treatment of Atherosclerosis. Darwitan A; Wong YS; Nguyen LTH; Czarny B; Vincent A; Nedumaran AM; Tan YF; Muktabar A; Tang JK; Ng KW; Venkatraman S Adv Healthc Mater; 2020 Jul; 9(14):e2000465. PubMed ID: 32543010 [TBL] [Abstract][Full Text] [Related]
9. Folate-Modified Liposomes Loaded with Telmisartan Enhance Anti-Atherosclerotic Potency for Advanced Atherosclerosis in ApoE Fang D; Jin Q; Jin Z; Wang F; Huang L; Yang Y; He Z; Liu Y; Jiang C; Wu J; Song X J Biomed Nanotechnol; 2019 Jan; 15(1):42-61. PubMed ID: 30480514 [TBL] [Abstract][Full Text] [Related]
10. Bifunctional supramolecular nanofiber inhibits atherosclerosis by enhancing plaque stability and anti-inflammation in apoE Shang Y; Ma C; Zhang J; Wang Z; Ren C; Luo X; Peng R; Liu J; Mao J; Shi Y; Fan G Theranostics; 2020; 10(22):10231-10244. PubMed ID: 32929345 [No Abstract] [Full Text] [Related]
11. The role of marine omega-3 (n-3) fatty acids in inflammatory processes, atherosclerosis and plaque stability. Calder PC Mol Nutr Food Res; 2012 Jul; 56(7):1073-80. PubMed ID: 22760980 [TBL] [Abstract][Full Text] [Related]
12. Role of Omega-3 Fatty Acids in Cardiovascular Disease: the Debate Continues. Sherratt SCR; Libby P; Budoff MJ; Bhatt DL; Mason RP Curr Atheroscler Rep; 2023 Jan; 25(1):1-17. PubMed ID: 36580204 [TBL] [Abstract][Full Text] [Related]
13. Insulin-Like Growth Factor-1 Receptor Deficiency in Macrophages Accelerates Atherosclerosis and Induces an Unstable Plaque Phenotype in Apolipoprotein E-Deficient Mice. Higashi Y; Sukhanov S; Shai SY; Danchuk S; Tang R; Snarski P; Li Z; Lobelle-Rich P; Wang M; Wang D; Yu H; Korthuis R; Delafontaine P Circulation; 2016 Jun; 133(23):2263-78. PubMed ID: 27154724 [TBL] [Abstract][Full Text] [Related]
14. EphA2 Expression Regulates Inflammation and Fibroproliferative Remodeling in Atherosclerosis. Finney AC; Funk SD; Green JM; Yurdagul A; Rana MA; Pistorius R; Henry M; Yurochko A; Pattillo CB; Traylor JG; Chen J; Woolard MD; Kevil CG; Orr AW Circulation; 2017 Aug; 136(6):566-582. PubMed ID: 28487392 [TBL] [Abstract][Full Text] [Related]
15. Effect of eicosapentaenoic acid/docosahexaenoic acid on coronary high-intensity plaques detected with non-contrast T1-weighted imaging (the AQUAMARINE EPA/DHA study): study protocol for a randomized controlled trial. Nakao K; Noguchi T; Asaumi Y; Morita Y; Kanaya T; Fujino M; Hosoda H; Yoneda S; Kawakami S; Nagai T; Nishihira K; Nakashima T; Kumasaka R; Arakawa T; Otsuka F; Nakanishi M; Kataoka Y; Tahara Y; Goto Y; Yamamoto H; Hamasaki T; Yasuda S Trials; 2018 Jan; 19(1):12. PubMed ID: 29310688 [TBL] [Abstract][Full Text] [Related]
16. Docosahexaenoic acid supplementation modifies fatty acid incorporation in tissues and prevents hypoxia induced-atherosclerosis progression in apolipoprotein-E deficient mice. Van Noolen L; Bäck M; Arnaud C; Rey A; Petri MH; Levy P; Faure P; Stanke-Labesque F Prostaglandins Leukot Essent Fatty Acids; 2014 Oct; 91(4):111-7. PubMed ID: 25139400 [TBL] [Abstract][Full Text] [Related]
18. Methyl-CpG-binding 2 K271 lactylation-mediated M2 macrophage polarization inhibits atherosclerosis. Chen L; Zhang M; Yang X; Wang Y; Huang T; Li X; Ban Y; Li Q; Yang Q; Zhang Y; Zheng Y; Wang D; Wang X; Shi X; Zhang M; Sun Y; Wu J Theranostics; 2024; 14(11):4256-4277. PubMed ID: 39113793 [No Abstract] [Full Text] [Related]
19. Complement Receptor Targeted Liposomes Encapsulating the Liver X Receptor Agonist GW3965 Accumulate in and Stabilize Atherosclerotic Plaques. Benne N; Martins Cardoso R; Boyle AL; Kros A; Jiskoot W; Kuiper J; Bouwstra J; Van Eck M; Slütter B Adv Healthc Mater; 2020 May; 9(10):e2000043. PubMed ID: 32329226 [TBL] [Abstract][Full Text] [Related]
20. Protective role of n6/n3 PUFA supplementation with varying DHA/EPA ratios against atherosclerosis in mice. Liu L; Hu Q; Wu H; Xue Y; Cai L; Fang M; Liu Z; Yao P; Wu Y; Gong Z J Nutr Biochem; 2016 Jun; 32():171-80. PubMed ID: 27142749 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]